M.J. De Miguel Luken - START Madrid-Centro Integral Oncológico Clara Campal, Sanchinarro University Hospital

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 9 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

36P Selpercatinib treatment beyond progression (PD) in RET fusion-positive NSCLC: Association with pattern of PD

M.J. De Miguel Luken, B. Besse, Y.J. Kim, M.L. Johnson, J. Chan, P. Peterson, S. Szymczak, T. Puri, D.S.W. Tan

ESMO Open (2024)

引用0浏览0引用

671P Safety and efficacy of PM060184 plus gemcitabine in advanced solid tumors

S. Goel,M. Provencio Pulla,M.J. De Miguel Luken, M. Ghalib,V. Calvo de Juan, M.B. Hammami, S. Vikash, R. Maitra, I. Chaudhary,S. Martinez, C. Kahatt, S. Extremera,

Annals of Oncology (2023): S472

引用0浏览0引用

1048P Phase I/II Study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, with unresectable locally advanced or metastatic cancer

N. Kotecki, S. Rottey, E. Garralda, V. Galvao,M.J. De Miguel Luken,O. Saavedra Santa Gadea, V. Boni, J. Johnson, J.P. McNally, A. McEwen, S. Murphy, S. Singhal,

Annals of Oncology (2023): S635-S635

引用0浏览0引用

694P Full efficacy analysis of phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy in refractory solid tumors

P. Bono, L. Verlingue,M.J. De Miguel Luken, A. Pasanen, D. Robbrecht, T. Skyttä, S.M.E. Iivanainen, S. Shetty,Y.T. Ma, D.M. Graham, S.P. Arora, P.M. Jaakkola,

Annals of Oncology (2023): S483-S484

引用0浏览0引用

655O Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC)

B.C. Cho,M.L. Johnson, J. Bar, E. Schaefer, K. Yoh, A. Zer, M.T. Moskovitz,S-H. Lee,V. Moreno Garcia,M.J. De Miguel Luken, Y. Okuma, J-H. Kim,

Annals of Oncology（2023）

引用0浏览0引用

654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study

B.T. Li, F. Meric-Bernstam, A. Bardia, Y. Naito,S. Siena, P.G. Aftimos, I. Anderson, G. Curigliano,M.J. De Miguel Luken, M. Kalra,D-Y. Oh, J.O. Park,

Annals of Oncology (2023): S459-S460

引用0浏览0引用

1989MO Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II LUPER study

A. Calles Blanco,A.F. Navarro Mendivil,B. Doger de Spéville, E. Álvarez Colomé,M.J. De Miguel Luken,R.M. Alvarez,V. Moreno Garcia,J. ramon,M. Arregui Valles,E. Corral de la Fuente, D. Alcalá, M. Fernández,

Annals of Oncology (2023): S1060-S1061

引用0浏览0引用

175P Safety and preliminary efficacy of GEN1042 (DuoBody-CD40x4-1BB) combination therapy in patients with advanced solid tumors

I. Melero, E. Grande Pulido,M.J. De Miguel Luken, M.L. Johnson, J.R. Bauman,V. Moreno Garcia, A.O. Walter, H. Adams, Ö. Türeci,G. Russo,U. Sahin, J. Steinberg,

Immuno-Oncology and Technology (2022)

引用0浏览0引用

196TiP A phase I study of REGN6569, a GITR monoclonal antibody (mAb), in combination with cemiplimab in patients with advanced solid tumour malignancies

N. Lakhani, O. Hamid, I. Braña, P. Reguera Puertas, M.P. Lopez Criado,P.L. Swiecicki,M.J. De Miguel Luken,M. Gil Martín, H. Khong,V. Moreno Garcia,M.J. Lostes Bardaji, F. Sun,

Immuno-Oncology and Technology (2022): 100308

引用0浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn